Latest news with #BiocomCalifornia
Business Wire
2 days ago
- Business
- Business Wire
Biocom California and Los Angeles County Economic Development Corporation Renew Memorandum of Understanding to Advance the Greater Los Angeles Life Science Ecosystem
LOS ANGELES & SAN DIEGO & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Biocom California, the association representing the California life science industry, and the Los Angeles County Economic Development Corporation (LAEDC), a leader in inclusive economic growth, today announced the renewal of a Memorandum of Understanding (MOU) aimed at strengthening the life science ecosystem in the Greater Los Angeles region. 'Greater Los Angeles is home to a thriving life science cluster, powered by world-class research institutions and a diverse, innovation-driven economy,' said Dan Gober, Executive Director, Los Angeles of Biocom California. 'This renewed partnership with LAEDC enables us to double down on the commitment we made when we first opened our Greater LA office in 2015 to address the unique needs of the LA life science community, connect it with complementary regional hubs across Southern California, and ensure that groundbreaking discoveries made here stay and scale here.' Under the MOU, Biocom California and LAEDC will collaborate on strategic programs and initiatives to support growth and innovation in Los Angeles County's bioscience sector. Key objectives include aligning resources and networks to: Identify the unique needs of the Greater LA life science cluster Strengthen connections across the Southern California life science ecosystem Retain and grow discoveries and businesses within California Drive economic development through talent, capital, and policy initiatives Los Angeles County is a critical player in the global bioeconomy, bolstered by internationally renowned institutions such as UCLA, USC, Cedars-Sinai Medical Center, Caltech and City of Hope. The region is home to more than 3,966 life science establishments, providing close to 200,000 jobs and generating over $60 billion in economic output. In 2024 alone, the region secured $1.51 billion in federal funding from the NIH and NSF, underscoring its prominence as a center of scientific advancement. 'LAEDC's partnership with Biocom California reflects our shared vision for inclusive and sustainable economic growth driven by innovation,' said Stephen Cheung, president and CEO of LAEDC. 'The life sciences are essential to that vision: delivering transformative health outcomes, creating quality jobs, and strengthening our position in global markets. Together, we will continue to support and elevate this high-impact industry throughout Los Angeles County.' The MOU also outlines collaboration on signature events, joint policy and workforce initiatives, and the implementation of the LA County Bioscience Strategic Plan. Both organizations will engage public and private stakeholders, leveraging their unique assets to accelerate the life sciences sector's impact on local communities and the broader economy. About Biocom California Biocom California is the leader and advocate for California's life science sector. We work on behalf of our members to drive public policy, build an enviable network of industry leaders, create access to capital, introduce cutting-edge STEM education programs and create robust value-driven purchasing programs. Founded in 1995 in San Diego, Biocom California provides the strongest public voice to research institutions and companies that fuel the local and state-wide economy. Our goal is simple: to help our members produce novel solutions that improve the human condition. In addition to our San Diego headquarters, Biocom California operates core offices in Los Angeles and the San Francisco Bay Area, with satellite offices in Sacramento, Washington, D.C. and Tokyo. Our broad membership benefits apply to biotechnology, pharmaceutical, medical device, genomics and diagnostics companies of all sizes, as well as to research universities and institutes, clinical research organizations, investors and service providers. For more information on Biocom California, please visit our website at Connect with us on LinkedIn, Facebook and X.
Business Wire
26-06-2025
- Business
- Business Wire
Biocom California's 2025 Economic Impact Report Highlights Importance of the State's Life Science Industry -- One of the Top Industries in the Fourth Largest Economy in the World
SOUTH SAN FRANCISCO, Calif. & LOS ANGELES & SAN DIEGO--(BUSINESS WIRE)--Biocom California, the association representing the California life science industry, today released its 2025 Life Science Economic Impact Report, providing the most comprehensive report to date of the industry's economic footprint, innovation output and national leadership. 'California's life science industry remains a cornerstone of economic vitality and a global leader in health innovation." According to the report, the life science industry in California generated $396 billion in total business output, supported approximately 1.15 million jobs and played a central role in the development of at least 12 novel therapies approved by the U.S. Food and Drug Administration in 2024—more than any other state. 'California's life science industry remains a cornerstone of economic vitality and a global leader in health innovation,' said Tim Scott, president and CEO of Biocom California. 'Even amid economic tightening and political uncertainty, our sector continues to drive the discovery and delivery of life-changing treatments, medical devices and diagnostics around the world.' Scott continued: 'In a second consecutive year of economic headwinds, California's life science entrepreneurs remain a force of unstoppable resilience. They continue to advance bold science, build new ventures and deliver innovation that improves lives around the world. We are honored to champion their work at every stage. From policy advocacy and capital connections to workforce development, group purchasing, and strategic partnerships, our commitment to supporting our members has never been stronger.' This year's report features stories that highlight the medicines born in California and the scientific visionaries behind them. It is a tribute to the scientists, founders and teams across the state whose work delivers hope and health to patients worldwide. Key Findings from Biocom California's 2025 Life Science Economic Impact Report: California's life science industry generated $396 billion in total business output and directly employed more than 452,000 Californians in 2024, with a broader economic footprint supporting approximately 1.15 million jobs in the state. The state's life science ecosystem contributed directly to at least 12 of the 50 novel therapies approved by the U.S. F.D.A. in 2024 including medicines to treat cancer, rare diseases, mental health disorders, infectious diseases and more. The state leads the nation in biomanufacturing, providing over 141,000 direct life science manufacturing jobs, representing 31.2% of California's life science payroll employment. California research institutions received $5.7 billion in funding from the National Institutes of Health (NIH) and National Science Foundation (NSF) in 2024—the highest of any U.S. state. The state attracted $63.1 billion in private capital, including major venture and mergers and acquisitions (M&A) transactions, despite headwinds in the capital markets. Life-Saving Therapies Nurtured by Public and Private Investment California is the most productive hub for the development of innovative treatments of disease, many of which are supported by public investment. In 2024, California researchers received a total of $5.7 billion in federal funding from the NIH and NSF, more than any other U.S. state. These grants supported a range of health-related areas of research, including Alzheimer's disease and related dementias, stimulants, pain management, Lyme and tick-borne diseases, antimicrobial resistance, universal flu vaccine, mental health research and others. Also critical to the health of the life science industry is private investment in the form of venture capital and corporate M&A transactions. Total 2024 private sector investment in California came to $63.1 billion, which includes private equity and funding realized through the initial public offering process. Venture investment, typically raised by earlier stage companies, is important to establish early data showing the potential of new therapeutic approaches, which often originate in academia. M&A investment is frequently necessary to fully realize the potential of those new therapeutic approaches, as venture-funded companies frequently lack the resources to execute large, late-stage clinical studies and the corporate infrastructure necessary for commercialization of innovative technologies. California is the Biomanufacturing Leader Biocom California's Economic Impact Report found that 31.2% of life science payroll jobs in 2024 were in biomanufacturing, for a total of 141,000 jobs. Robust manufacturing capabilities are vital for global health impact, emergency preparedness, compliance with environmental and regulatory requirements. Such capabilities tend to have an out-sized impact on local economies due to labor-intensive processes, supply chain complexity and high-value raw material inputs. Importantly, biomanufacturing offers a pathway to living-wage careers, averaging $135,147 per year in California, for individuals with associate's degrees. In fact, 42% of life science degrees awarded in the state in 2024 were at the associate's level. 'The life science industry provides valuable jobs to Californians from a wide range of educational backgrounds,' said Scott. 'The prevalence of jobs specifically in manufacturing demonstrates a robust path into the life science industry for California residents from all economic backgrounds, and many community colleges are partnering with industry leaders to develop educational curricula to meet the needs of biomanufacturing companies.' California Brings Life-Saving Medicines to Patients In 2024, 50 unique novel drugs were approved by the U.S. FDA, and at least 12 of those came from California-headquartered companies addressing disease areas such as cancer, muscular dystrophy, heart disease and more. 'Patients from all over the world benefit from the innovation driven by the life science ecosystem in California, and citizens of the state benefit from the direct jobs and the overall economic impact,' concluded Mr. Scott. 'We invite the public as well as state and federal legislators and municipalities to learn more about the industry, its life-saving therapies and its economic impact. The California life science industry is a force behind the world's fourth largest economy and a source of pride for Californians.' To access the full report, visit About Biocom California Biocom California is the leader and advocate for California's life science sector. We work on behalf of our members to drive public policy, build an enviable network of industry leaders, create access to capital, introduce cutting-edge STEM education programs and create robust value-driven purchasing programs. Founded in 1995 in San Diego, Biocom California provides the strongest public voice to research institutions and companies that fuel the local and state-wide economy. Our goal is simple: to help our members produce novel solutions that improve the human condition. In addition to our San Diego headquarters, Biocom California operates core offices in Los Angeles and the San Francisco Bay Area, with satellite offices in Sacramento, Washington, D.C. and Tokyo. Our broad membership benefits apply to biotechnology, pharmaceutical, medical device, genomics and diagnostics companies of all sizes, as well as to research universities and institutes, clinical research organizations, investors and service providers. For more information on Biocom California, please visit our website at Connect with us on LinkedIn, Facebook and X.
Business Wire
04-06-2025
- Business
- Business Wire
Biocom California Appoints New Members to Its Board of Directors and Board of Governors
SOUTH SAN FRANCISCO, Calif. & LOS ANGELES & SAN DIEGO--(BUSINESS WIRE)--Biocom California, the association representing the California life science industry, today announced the appointment of Thierry Diagana, Ph.D., head of Global Health and California sites head for Novartis Biomedical Research; Stephen Hatke, vice president of operations and site head at Takeda's Thousand Oaks facility; and Kelly Hayes, assurance partner at Ernst & Young, to its board of directors. Additionally, Adam Lenain, member at Mintz Levin; Aaron K. Cohen, vice president, government affairs and public policy at Neurocrine Biosciences; and Diane Simeone, M.D., director of the Moores Cancer Center at University of California San Diego, were appointed to the board of governors. 'The addition of these accomplished leaders, scientists and policy changers brings strategic depth to our board of directors and board of governors,' said Tim Scott, president and CEO of Biocom California. 'Their expertise in capital raising, public policy and research will help shape our strategic priorities and ensure we continue supporting our member organizations as they navigate today's complex life science and drug development landscape.' Board of Directors Appointees Thierry Diagana leads Global Health at Novartis Biomedical Research, focusing on discovering new treatments and prevention methods for significant global medical needs. He conducted his Ph.D. research at the Pasteur Institute in Paris, France, and his post-doctoral studies at the Salk Institute in La Jolla, California. He joined the Novartis Institute for Tropical Diseases (Singapore) in 2007 to oversee the malaria program, resulting in two drug candidates that are now in Phase II clinical trials. Prior to this role, he gained expertise in drug discovery at Exelixis and therapeutic approaches to neglected tropical diseases at the Institute for OneWorld Health. In 2017, Dr. Diagana relocated to Emeryville, California, and has served as a member of Biocom California's board of governors since 2021. With more than 25 years of experience, Stephen Hatke is currently the vice president of operations and site head at Takeda's Thousand Oaks facility. Mr. Hatke first joined Takeda in the plasma business unit as head of manufacturing fractionation in Los Angeles. He also led many key initiatives including the Baby Big Campaign, Plasma Fractionation 'Factory of Future' strategy development, and the Thousand Oaks site transformation. Prior to joining Takeda, Mr. Hatke spent 15 years with Amgen in various roles including director manufacturing technologies, director of manufacturing and plant engineering manager. He holds a bachelor of science in electrical engineering from Purdue University and an MBA from Colorado State University. As an assurance partner at Ernst & Young, Kelly Hayes has significant experience in a variety of industries including medical technology, pharmaceutical, and biotechnology for both privately-held and publicly-traded entities. She has assisted clients in IPOs, follow-on offerings, the transition to 404(b) requirements associated with internal controls, collaboration agreements, mergers and acquisitions and various other '34 Act filings. Mrs. Hayes holds a bachelor of accountancy from San Diego State University. She is a CPA in California and a member of the AICPA. Board of Governors Appointees Adam Lenain is a member at Mintz Levin and routinely assists public and private life sciences companies and their investors in navigating complex legal and business issues throughout the corporate life cycle. He has over twenty-five years of experience representing clients in seed and venture capital financings, public offerings, reverse mergers, PIPEs, mergers and acquisitions, SEC Compliance, and complex commercial transactions and was recently named Biotechnology and Life Sciences Practice Lawyer of the Year in San Diego for 2025 by Best Lawyers in America. Mr. Lenain received a bachelor of arts degree from Yale University and a J.D. from University of San Diego School of Law. Aaron K. Cohen leads the federal and state government affairs and public policy teams as the head of Neurocrine Biosciences' Washington, D.C. office. He has over 25 years of experience in public policy and political strategy on Capitol Hill and in the private sector. Mr. Cohen's career includes working for two members of the U.S. Senate, both as chief of staff and healthcare policy advisor, with successes in authoring and facilitating the passage of multiple pieces of legislation through Congress on healthcare issues specific to Medicare beneficiaries, providers, women's health, and animal health that were signed into law. In the private sector and prior to joining Neurocrine, he represented a wide array of clients in government affairs and led on securing legislative and regulatory victories on issues such as health care, tax policy, and veterans' affairs. He also has advised and worked on several political campaigns at the federal, state, and local level. Mr. Cohen holds a bachelor of arts in political science from Pepperdine University. Diane Simeone, M.D., is the director for Moores Cancer Center at UC San Diego and provides the overall strategic and intellectual direction for the center's research programs, administrative structure, and multidisciplinary cancer clinical care. She serves as the principal investigator for the center's comprehensive cancer center grant sponsored by the National Cancer Institute (NCI). Dr. Simeone partners with academic and clinical leaders to guide cancer research and care and provides counsel to campus and university-level committees. Prior to her current role, she served as the director of the Pancreatic Cancer Center and was the associate director of translational research at Perlmutter Cancer Center at New York University Langone Health. She is an internationally renowned pancreatic surgeon and researcher with a long-standing career focused on treating pancreatic cancer and pancreatic cystic tumors. Dr. Simeone also served as the chair of the scientific and medical advisory board of the Pancreatic Cancer Action Network and is a past president of the American Pancreatic Association and Society of University Surgeons. She is an elected member of the National Academy of Medicine and served on the National Cancer Institute (NCI) Pancreatic Cancer Task force and the NCI Cancer Centers Study Section. She also serves on the Board of Directors for the National Comprehensive Cancer Network. She is the principal investigator of IMPACT PANC, a national clinical trials consortium focused on next generation clinical trials for patients with pancreatic cancer. She is also the founder of the Pancreatic Cancer Early Detection (PRECEDE) Consortium, an international consortium established to drive the early detection of pancreatic cancer. Dr. Simeone completed her residency at the University of Michigan and earned her medical degree at Duke University. About Biocom California Biocom California is the leader and advocate for California's life science sector. We work on behalf of our members to drive public policy, build an enviable network of industry leaders, create access to capital, introduce cutting-edge STEM education programs and create robust value-driven purchasing programs. Founded in 1995 in San Diego, Biocom California provides the strongest public voice to research institutions and companies that fuel the local and state-wide economy. Our goal is simple: to help our members produce novel solutions that improve the human condition. In addition to our San Diego headquarters, Biocom California operates core offices in Los Angeles and the San Francisco Bay Area, with satellite offices in Sacramento, Washington, D.C. and Tokyo. Our broad membership benefits apply to biotechnology, pharmaceutical, medical device, genomics and diagnostics companies of all sizes, as well as to research universities and institutes, clinical research organizations, investors and service providers. For more information on Biocom California, please visit our website at Connect with us on LinkedIn, Facebook and X.
Business Wire
14-05-2025
- Health
- Business Wire
Biocom California Opposes Most Favored Nation Price Setting Policy
SOUTH SAN FRANCISCO, Calif. & LOS ANGELES & SAN DIEGO--(BUSINESS WIRE)--Biocom California, the association representing the life science industry of California, issued the following statement in response to the recent Executive Order on Most Favored Nation price setting policy. This statement may be attributed to Tim Scott, president and CEO of Biocom California: 'Most Favored Nation (MFN) is a concept that has been proposed and rejected many times over the years for very good reasons: it would deny Americans timely access to the most innovative therapies and hamper biomedical innovation. The harm to patients would be immediate. The U.S. produces two-thirds of the world's medicines and gives hope to millions of patients around the world. Patients in the U.S. have access to 90 percent of existing medicines – a striking difference from our European counterparts, whose governments dictate which medicines are available. Price controls also affect how long it takes for medicines to reach patients once they are approved. MFN models send the wrong message to innovators and investors who need a solid, fair and value-based market environment to research and develop the next generation of breakthrough medicines. California, the world's leader in biomedical innovation, would be among the first to suffer. We agree with the Administration that American patients should not bear the cost of innovation alone and pay more than Europeans, but we need to address the root cause of the problem. Our health care system is one of the most complex and layered in the world, with Pharmacy Benefit Managers (PBMs), insurers and hospitals all demanding payments from innovators to provide medicines to patients, which significantly increases their cost for no added value. Over the years, we have worked cooperatively and successfully with regulatory and legislative offices at all levels of government. While Biocom California maintains its opposition to MFN and other international reference pricing schemes, we stand ready to continue to work with both Congress and the Administration to deliver world-class treatments and cures that patients can afford.' About Biocom California Biocom California is the leader and advocate for California's life science sector. We work on behalf of our members to drive public policy, build an enviable network of industry leaders, create access to capital, introduce cutting-edge STEM education programs and create robust value-driven purchasing programs. Founded in 1995 in San Diego, Biocom California provides the strongest public voice to research institutions and companies that fuel the local and state-wide economy. Our goal is simple: to help our members produce novel solutions that improve the human condition. In addition to our San Diego headquarters, Biocom California operates core offices in Los Angeles and the San Francisco Bay Area, with satellite offices in Sacramento, Washington, D.C. and Tokyo. Our broad membership benefits apply to biotechnology, pharmaceutical, medical device, genomics and diagnostics companies of all sizes, as well as to research universities and institutes, clinical research organizations, investors and service providers. For more information on Biocom California, please visit our website at Connect with us on LinkedIn, Facebook and X.
Yahoo
14-05-2025
- Health
- Yahoo
Biocom California Opposes Most Favored Nation Price Setting Policy
SOUTH SAN FRANCISCO, Calif. & LOS ANGELES & SAN DIEGO, May 14, 2025--(BUSINESS WIRE)--Biocom California, the association representing the life science industry of California, issued the following statement in response to the recent Executive Order on Most Favored Nation price setting policy. This statement may be attributed to Tim Scott, president and CEO of Biocom California: "Most Favored Nation (MFN) is a concept that has been proposed and rejected many times over the years for very good reasons: it would deny Americans timely access to the most innovative therapies and hamper biomedical innovation. The harm to patients would be immediate. The U.S. produces two-thirds of the world's medicines and gives hope to millions of patients around the world. Patients in the U.S. have access to 90 percent of existing medicines – a striking difference from our European counterparts, whose governments dictate which medicines are available. Price controls also affect how long it takes for medicines to reach patients once they are approved. MFN models send the wrong message to innovators and investors who need a solid, fair and value-based market environment to research and develop the next generation of breakthrough medicines. California, the world's leader in biomedical innovation, would be among the first to suffer. We agree with the Administration that American patients should not bear the cost of innovation alone and pay more than Europeans, but we need to address the root cause of the problem. Our health care system is one of the most complex and layered in the world, with Pharmacy Benefit Managers (PBMs), insurers and hospitals all demanding payments from innovators to provide medicines to patients, which significantly increases their cost for no added value. Over the years, we have worked cooperatively and successfully with regulatory and legislative offices at all levels of government. While Biocom California maintains its opposition to MFN and other international reference pricing schemes, we stand ready to continue to work with both Congress and the Administration to deliver world-class treatments and cures that patients can afford." About Biocom California Biocom California is the leader and advocate for California's life science sector. We work on behalf of our members to drive public policy, build an enviable network of industry leaders, create access to capital, introduce cutting-edge STEM education programs and create robust value-driven purchasing programs. Founded in 1995 in San Diego, Biocom California provides the strongest public voice to research institutions and companies that fuel the local and state-wide economy. Our goal is simple: to help our members produce novel solutions that improve the human condition. In addition to our San Diego headquarters, Biocom California operates core offices in Los Angeles and the San Francisco Bay Area, with satellite offices in Sacramento, Washington, D.C. and Tokyo. Our broad membership benefits apply to biotechnology, pharmaceutical, medical device, genomics and diagnostics companies of all sizes, as well as to research universities and institutes, clinical research organizations, investors and service providers. For more information on Biocom California, please visit our website at Connect with us on LinkedIn, Facebook and X. View source version on Contacts Biocom California Media Contact: Carolyn HawleyInizio Evoke Comms(619) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
